Introduction {#Sec1}
============

Atypical parkinsonian disorders (APDs) comprise a heterogeneous group of neurodegenerative diseases that share clinical features with idiopathic Parkinson's disease, but generally do not respond well to antiparkinsonian medications^[@CR1]^. Most cases of APDs are sporadic but rare familial forms have also been reported^[@CR2],[@CR3]^. Epidemiological studies have previously associated stressors such as environmental toxins and oxidative stress with the etiology of APDs^[@CR4]--[@CR6]^. Post-mortem studies have grouped APDs as protein accumulation disorders (e.g. proteinopathies) based on cellular protein aggregates^[@CR7]--[@CR9]^. Notably, the molecular and cellular processes that translate stress into protein aggregation and neurodegeneration in most APDs remain poorly understood.

Stress granules (SGs) are cytoplasmic foci formed in response to cellular stress mainly to minimize stress-related RNA damage and to promotes cell survival^[@CR10]^. Recently, several reports suggested that defective stress granules play a pathogenic role in several proteinopathies^[@CR11]--[@CR16]^. Observations such as elevated levels of oxidized RNA products in the cerebrospinal fluid and protein aggregates colocalizing with stress granule markers in some APDs indirectly support their involvement^[@CR6],[@CR14],[@CR15],[@CR17]^. In this study, we investigated the genetic basis of a familial APD segregating as autosomal dominant condition and found a rare stop-gain variant in the stress granule associated protein PABPC4L as an underlying cause.

Materials and Methods {#Sec2}
=====================

Study participants {#Sec3}
------------------

Research procedures were performed in accordance with the Declaration of Helsinki. Approval of the study was obtained from the Institutional Review Board of the Institute of Biomedical and Genetic Engineering Islamabad. Written informed consent was obtained from all participants. A family with six members (Fig. [1A](#Fig1){ref-type="fig"}; III:1, III:3, IV:4, IV:7, IV:9 and IV:11) exhibiting a progressive neurodegenerative disease manifesting primarily as atypical parkinsonism was identified by M.B. who diagnosed and treated the patients at Pakistan Institute of Medical Sciences Islamabad. The MRI of patients with ataxia (III:1 and IV:7) were examined by M.A.B. A team of neurologists headed by M.B. examined the patients and provided the clinical records.Figure 1Clinical characteristics and genetic analysis of the family. (**A**) Pedigree of the family showing co-segregation of the stop-gain variant p.R271X in PABPC4L with atypical Parkinsonism. Squares represent males, and circles females. Shaded symbols indicate individuals that received a clinical diagnosis (see Table [1](#Tab1){ref-type="table"} for details of clinical information). The arrow indicates index patient. Individuals selected for WGS are marked with an asterisk. Deceased individuals are marked with diagonal lines. The family members provided retrospective information of affection status of the deceased individuals (II:3, II:6, III:11 and IV:2). Affection status of individuals in the first generation (I:1 and I:2) could not be ascertained. Question marks in the first generation indicate unknown affection status. Genotypes: +/+, homozygous for wild-type allele; and +/p.R271X, heterozygous. (**B**) MRI of brain of patient III:1 (top panel) and IV:7 (bottom panel). Both patients show comparable cerebellar atrophy with dilation of the fourth ventricle. In the patient III:1 (top panel) a retrocerebellar arachnoid cyst can be seen as an incidental finding, whereas the atrophy of the cerebellum is obvious. (**C**) Left panel: Analysis pipeline used in the identification of the candidate variants. Right panel: Representative Sanger sequencing chromatograms of an unaffected and affected family member illustrating the stop-gain variant c.C811T; p.271X in the PABPC4L. Grey highlighting indicates the variant position. Predicted consequence at the translational level is also shown. Sanger sequencing of additional affected and unaffected family members showed that the c.C811T; p.271X variant in PABPC4L segregated with the disease (Supplementary File [1](#MOESM1){ref-type="media"}).

Whole genome sequencing and quality control {#Sec4}
-------------------------------------------

Whole genome sequencing was performed for two affected (III:1, IV:11) and two unaffected family members (III:6, IV:12). Genomic DNA was isolated from peripheral blood cells using standard methods^[@CR18]^. Libraries were prepared using the TruSeq Nano DNA PCR-free kit (Illumina San Diego CA USA). Paired-end sequencing (2 × 150 bp) was performed at \>30× coverage per sample on Illumina HiSeqX TEN (Illumina San Diego CA). Raw reads were aligned to the human reference genome (version build GRCh37, version hs37d5) using bwa mem (version 0.7.8)^[@CR19]^ with minimum base quality threshold set to zero \[-T 0\] and remaining settings left at default values. Duplicates were marked using Picard version (1.125)^[@CR20]^. Single nucleotide variants (SNVs) were called using SAMtools (version 0.1.19)^[@CR21]^ and short indels were called using Platypus (version 0.7.4)^[@CR22]^. Functional classifications of the variants were done using ANNOVAR^[@CR23]^ with gene model definitions from Gencode (version v19).

Variant filtering and selection {#Sec5}
-------------------------------

Variants with base quality Q score \<20, minimum coverage \<10X, or a minor allele frequency MAF \>0.001 in ExAC (version 0.3) or MAF \>0.01 in the 1000 genomes were removed. Thereafter all functional mutations including: nonsynonymous SNVs; frameshift and non -frameshift indels; and stop-gain or stop-loss or splice-site SNVs or Indels were carried forward and were evaluated for deleteriousness using CADD \[24\] and a set of prediction tools including SIFT, PolyPhen2, LRT, Mutation Taster, FATHMM, PROVEAN, MetaSVM and MetaLR \[25--31\]. The WGS variants complying with the autosomal dominant mode of inheritance and segregating in the patients and not in controls were prioritized for Sanger sequencing validation and co-segregation testing in the extended pedigree.

Sanger validation and co-segregation analysis {#Sec6}
---------------------------------------------

The genomic regions harboring prioritized variants were amplified using predesigned commercially obtained M13-tailed primer pairs \[Primer ID (Gene_ID) Hs00253986_CE (*PABPC4L*), Hs00278134_CE (*ZNF292*), Hs00278167_CE (C6orf163), Thermo Fischer Scientific Inc.\]. Thermocycling conditions used were as follows: 3 min at 94 °C, 30 cycles of 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 45 s, and the final extension for 5 min at 72 °C. The PCR products were resolved on 1.5% agarose gel and amplified genomic fragments were purified using MinElute Gel Extraction Kit (Qiagen, Germany). Bi-directional Sanger sequencing was performed with M13 forward (TGTAAAACGACGGCCAGT) and reverse (CAGGAAACAGCTATGACC) primers (StarSEQ GmBH, Mainz, Germany).

Plasmid preparation {#Sec7}
-------------------

Full length cDNA of wild-type human *PABPC4L* (NCBI Reference Sequence: NM_001114734.2) was amplified from human adult brain cDNA using forward primer containing XhoI site:5′-CACCCTCGAGAC[ATGAATGTAGCAGCCAAGTACC]{.ul}-3′ and reverse primer containing XmaI site5′-ATATCCCGGG[CTAGTGTCTCTGGGCCAAGG]{.ul}-3′ (PABPC4L specific sequence is underlined). PCR product was digested with XhoI and XmaI and inserted into pmCherry-C1 vector (Clontech). *PABPC4L* cDNA clone carrying the c.C811T variant encoding p.R271X was generated using Phusion Site-Directed Mutagenesis Kit (Thermo Fischer Scientific Inc.) and mutagenic primer AGAAAGTCGAG[T]{.ul}GACAGGCTGAG (variant position is underlined) according to manufacturer's instructions. Flag-tagged PABPC4L constructs was generated with PCR using forward primer containing the FLAG tag encoding sequence GACTACAAAGACGATGACGACAAG containing HindIII site. Construct encoding G3BP1 (peGFP-C1-G3BP1) was kindly provided by Nancy Kedersha (Brigham and Women's Hospital, Boston, MA)^[@CR24]^. Plasmids were purified with GeneJET Plasmid Midiprep Kit (Thermo Fischer Scientific Inc.). Clones generated by PCR were confirmed by direct sequencing.

Cell culture and transfection {#Sec8}
-----------------------------

Human embryonic kidney 293 (HEK293) cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin--streptomycin (all from Gibco, Paisley, UK). Cells were cultured at 37 °C in a humidified atmosphere with 5% CO~2~. The medium was changed every 2--3 days. Cell cultures were tested for mycoplasma contamination prior to experiments using PCR Mycoplasma Test Kit I/C (PK-CA91-1024, PromoCell GmbH, Germany). For transient transfections, cells were plated either in 12 well plates or on glass covers slips coated with 200 μl of 0.01% poly-L-Lysine solution (sigma). Transfections were performed using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA). For induction of oxidative stress, cell culture medium was replaced with fresh complete Dulbecco's Modified Eagle's Medium (DMEM) growth media one hour prior to stress induction. Cells were stressed with sodium arsenite (0.5 mM, Sigma-Aldrich) for 45 min at 37 °C in an incubator with 5% CO~2~.

Western blotting {#Sec9}
----------------

HEK293 cells were washed twice with phosphate buffer saline (PBS) and lysed thirty-six hours post-transfection. Western blotting was performed with cell lysates containing 30 μg of proteins. After sodium dodecyl sulfate polyacrylamide gel electrophoresis, the proteins were transferred to polyvinylidene difluoride (PVDF) membrane, which was blocked in 10% skimmed milk for one hour. The membranes were then incubated with mouse anti-Flag (Sigma) overnight at 4 °C, followed by incubation with peroxidase-linked secondary antibodies (1:10,000) for one hour. Bands were detected on a ChemiDoc XRS+ imaging system (Bio-Rad). After Flag tag detection, PVDF membrane was stripped, and then subjected to detect beta-Actin expression using Rabbit anti-Actin antibody (1:1000, Abcam).

Cell imaging,quantification and analysis {#Sec10}
----------------------------------------

HEK293 cells grown and transfected on glass coverslips were washed three times with phosphate buffer solution (PBS) and were fixed in 4% paraformaldehyde for 10 minutes. Cells were washed again three times with PBS and nuclei were stained with 4′, 6′-diamidino-2-phenylindole (DAPI; Sigma, St Louis, MO, USA). Coverslips were then mounted onto slides with ProLong Gold *Antifade* Mountant (Thermo Fischer Scientific Inc.). Images were obtained with a 63x objective on a TCS SP5 confocal imaging system (Leica Microsystems, Heidelberg GmbH). The PABPC4L localization was quantified by calculating a nuclear to cytoplasmic ratio using Fiji software as described previously^[@CR25],[@CR26]^. Briefly, cells were imaged for mCherry (expressed as a fusion protein with wild-type or PABPC4L:p.R271X variant) and DAPI fluorescence. The nuclear area was identified by DAPI and cytoplasmic area as total mCherry signal minus nuclear area. We determined the integrated fluorescence intensity ratio of nuclear/cytoplasmic mCherry signal. Twenty-four cells for each condition from triplicate coverslips were processed and ratios were plotted using QtiPlot software. Stress granules (SGs) were identified by green fluorescent protein tagged RasGAP SH3 domain Binding Protein (G3BP-GFP) expression as described previously^[@CR27]^. Only cells with at least three G3BP-GFP positive foci with a size of 0.5--2.5 μm were included. Fiji software was used to quantify the integrated intensity of mCherry fluorescence (i.e PABPC4L) overlapping with GFP signal (i.e G3BP). At least thirty cells for each condition from triplicate coverslips were analyzed.

*In situ* hybridization {#Sec11}
-----------------------

Animal care and experimental procedures were performed in agreement with the German law on the use of laboratory animals (animal welfare act; TierSchG). All procedures involving mice were performed according to the protocols approved by the German Cancer Research Center institutional animal care and use committee and by the local responsible government department (Regierungspräsidium Karlsruhe). Brains from embryonic, developing and adult C57Bl/6 mice were frozen on dry ice and 15 μm sections were cut on a cryostat (Leica Microsystems, Germany). *In situ* hybridization experiments were carried out as described^[@CR28]^ with the radiolabeled oligodeoxyribonucleotide probes targeting the exon-exon junction region of the mouse *pabpc4l* mRNA transcript (NM_001101479):

\[5′-CTGCAGTCCATAACCTGGAAGCTACAGCCTTGAGAGCTGCAGGCTTGTA-3′\].

The probe was 3′ end-labeled with (a)-^33^P-dATP (Hartmann Analytic, Germany) using terminal deoxynucleotidetransferase (*Roche*, Basel, Switzerland). Brain sections were then incubated overnight in ahybridization mix containing 4 × SSC (0.6 M NaCl, 0.06 M sodium citrate), 50% formamide, 10% dextrane and 1 pg/μl labeled oligodeoxyribonucleotide probe at 42 °C and were subsequently washed three times at 56 °C for 30 min. Brain sections were then dehydrated and exposed to Kodak R X-omat AR film for 1 week. Control *in situ* hybridization was performed by adding excess amount (10x) of cold competitor (unlabeled probe) to the hybridization mix.

Statistical analysis {#Sec12}
--------------------

Data were plotted as mean and SD using QtiPlot. Shapiro-Wilk-test and Student's t-test were used for assessing normality of data and to compare means, respectively. P-values of less than 0.05 were considered statistically significant.

Results {#Sec13}
=======

The index patient III:1 (Fig. [1A](#Fig1){ref-type="fig"}, arrowhead), 47-year-old male, presented with two years history of walking difficulty, trouble in dressing and writing and problems with right hand coordination. On the neurological examination, spasticity on his left side and gait ataxia were noticed. His tendon reflexes in lower limbs were brisk and plantar responses were bilateral absent. During the next two years, he developed Parkinson-like symptoms comprising rigidity and bradykinesia as well as progression of his ataxia and downbeat nystagmus. In addition, his voice weakened, he suffered of dysarthria and dysautonomia with constipation and nocturia. His cognitive abilities were intact (MMSE score 28/30). Neuroimaging studies showed an atrophy of cerebellum, middle cerebellar peduncles and brainstem (Fig. [1B](#Fig1){ref-type="fig"}, top panel). There were no abnormalities in striatum, globus pallidus, corpus callosum and thalamus. Cerebrospinal fluid and serological investigations with a complete thyroid panel and B12 level were unremarkable. Patient III:3 (Fig. [1A](#Fig1){ref-type="fig"}), brother of index patient III:1, was diagnosed with parkinsonism, dysautonomia and insomnia at slightly younger age (42 years). He did not exhibit ataxia or tremor at the time of his diagnosis. His daughter (IV:4; Fig. [1A](#Fig1){ref-type="fig"}) exhibited unilateral tremor and rigidity in her right arm at the age of thirty-four. Patient IV:7(male) was first noticed at an age of 38 years with ataxic gait during his training as a soldier. He developed parkinsonian symptoms similar to patient III:1 with additional intention tremor and depression. He died during the course of this study at the age of 45 apparently due to cardiopulmonary arrest. His family members retrospectively informed us that he had developed difficulty breathing during sleep, forcing him to sleep upright to avoid dyspnea. Neuroimaging of IV:7 showed cerebellar atrophy with dilation of the fourth ventricle (Fig. [1A,B](#Fig1){ref-type="fig"} bottom panel). Two sisters of the patient IV:7 (Fig. [1A](#Fig1){ref-type="fig"}, IV:9 and IV:11) exhibited parkinsonism at the age of 37 and 35, respectively. Patients described here received levodopa for their parkinsonian symptoms, which did not improve symptoms even at high doses. Demographic and clinical description of all cases is summarized in Table [1](#Tab1){ref-type="table"}.Table 1Clinical characteristics of the affected family members.SexIII:1III:3IV:4IV:7IV:9IV:11MaleMaleFemaleMaleFemaleFemaleAge at onset, year474234383735Current age, year556538474340Initial SymptomsAtaxiaAkinesiaTremorAtaxiaTremorTremor**Neurologic findings**Akinesia++++++Spasticity+−−+−−Rigidity++++++Deep tendon reflexBriskNormalNormalBriskNormalNormalAtaxia+−−+−−Tremor−−++++**Other Symptoms**Autonomic disturbance++−++−Depression−−−+−−Sleepdisorder−+−+−−

Family-based analyses of the WGS data obtained for two affected and two unaffected members (asterisks in Fig. [1A](#Fig1){ref-type="fig"}) assuming an autosomal dominant mode of inheritance prioritized heterozygous variants in PABPC4L, ZNF292 and C6orf163 for sanger validation and disease co-segregation testing in the extended pedigree (Fig. [1C](#Fig1){ref-type="fig"}; left panel and Supplementary Table). Sanger sequencing of the three prioritized variants in four additional affected (Fig. [1A](#Fig1){ref-type="fig"}, III:3, IV:4, IV:7 and IV:9) and eleven unaffected biological relatives excluded ZNF292 and C6orf163 variants and identified the stop-gain variant c.C811T; p.R271X in the *PABPC4L* gene as the possible cause of parkinsonian disorder in the family (Supplementary Table). The c.C811T;p.R271X variant in *PABPC4L* is absent in the south Asian control cohort in the GnomAd^[@CR29]^ and in-house datasets. This variant was ranked among the top 0.1% most deleterious possible substitutions (CADD score 38).

PABPC4L gene is previously uncharacterized. Thus, we examined the spatiotemporal expression pattern of *pabpc4l* in the mouse brain. The level of *pabpc4l* transcript was low at embryonic day 15 (Fig. [2A](#Fig2){ref-type="fig"}; E15.5). There was a developmental upregulation of the *pabpc4l* transcript in the cerebellum with moderate signal intensity at P14 (Fig. [2A](#Fig2){ref-type="fig"}; P14) and strong intensity in the adult brain. The *pabpc4l* transcript was also detected in cortex, hippocampus, presubiculum, and regions of the brainstem of adult mice (Fig. [2A](#Fig2){ref-type="fig"}; Adult). In the adult human brain PABPC4L transcript was detected at higher levels in the hindbrain particularly in cerebellum whereas moderate expression was also detected in regions of midbrain and forebrain (Supplementary Fig. [2](#MOESM1){ref-type="media"}, credit: Human microarray data from the Allen Brain Atlas)^[@CR30]^.Figure 2Expression, subcellular localization and function of PABPC4L. (**A**) Distribution of *pabpc4l* mRNA in the developing and adult mouse brain. Sections were examined for *pabpc4l* mRNA expression at embryonic day 15.5 (E15.5), postnatal day 14 (P14) or at adult stage (ctx; cortex, cb; cerebellum, bs; brainstem). (**B**) Predicted structure of the PABPC4L protein. RRM; RNA recognition motifs. The variant position is indicated in red. (**C**) Left panel: Cellular distribution of mCherry-tagged wild-type and p.R271X variant containing PABPC4L in HEK293 cells. Wild-type PABPC4L-mCherry shows a nuclear distribution, whereas PABPC4L (p.R271X)-mCherry shows a uniform nucleo-cytoplasmic distribution in HEK293 cells. Red: mCherry fluorescence, Blue: DAPI nuclei. The panel on the right shows the nuclear to cytoplasmic ratio of the mCherry signal in HEK293 cells transfected with either wild-type PABPC4L-mCherry or p.R271X PABPC4L-mCherry plasmids. Right panel: Western blot analysis of FLAG-tagged wild-type and p.R271X variant containing PABPC4L in HEK293 cells. The p.R271X variant reduces the molecular weight of PABPC4L. (**D**) Wild type but not p.R271X variant PABPC4L localizes to G3BP-GFP-positive stress granules in Na-arsenite treated HEK293 cells. Red: PABPC4L-mCherry, green: G3BP-GFP. A region including G3BP-GFP positive foci is enlarged. The graph indicates the line scan analysis of the cytoplasmic region (green line: G3BP-GFP signal, red line: PABPC4L-mCherry signal) and shows the extent of colocalization. The bar graph on the right panel shows the quantification of red signal intensity overlapping with G3BP-GFP signal. t-test, Means ± S.D. \*\*\**p* = 0.0001.

The human *PABPC4L* transcript encodes a 370 amino acids protein (UniProt: P0CB38) predicted to contain four non-identical RNA recognition motifs (RRMs) (RRM1: 10--88, RRM2: 98--174, RRM3: 190--267 and RRM4: 293--369) characteristic of cytoplasmic type I polyadenylate-binding proteins (PABPs) i.e PABPC1, PABPC4 and PABPC5^[@CR31]^. The identified stop-gain variant p.R271X results in a shorter PABP4CL protein lacking the C-terminal RRM motif (RRM4: 293--369).

To investigate functional consequences of the PABPC4L variant p.R271X, we expressed wild-type and the truncated PABPC4L in HEK293 cells as mCherry or flag-tag fusion proteins. Since RRM motifs influence the subcellular localization of PABP proteins^[@CR32]^, we examined the subcellular localization of the wild-type and p.R271X variant PABPC4L proteins in HEK293 cells. Wild-type PABPC4L-mCherry fusion protein showed a predominantly nuclear localization in HEK293 cells. In stark contrast, the truncated PABPC4L variant exhibited a uniform nucleo-cytoplasmic localization with no aggregation in the nucleus, suggesting that the stop-gain variant impairs nuclear import or retention (Fig. [2C](#Fig2){ref-type="fig"}, Left panel).Detection of the truncated protein 48-hours post transfection at comparable levels with wild-type PABPC4L protein suggests that the variant does not result in increased degradation of the protein (Fig. [2C](#Fig2){ref-type="fig"}, right panel).

Cytoplasmic PABPs PABPC1 and PABPC4 have recently been identified to associate with RasGAP SH3 domain Binding Protein (G3BP) labeled stress granules^[@CR33],[@CR34]^. To test similar association of PABPC4L with RNA stress granules we exposed PABPC4L-mCherry transfected HEK293 cells to sodium arsenite induced oxidative stress and found a redistribution of wild-type PABPC4L from a predominantly nuclear to a focal cytoplasmic pattern. Moreover, PABPC4L-mCherry co-localized with the stress granule marker G3BP-GFP, indicating that PABPC4L associates with stress granules (Fig. [2D](#Fig2){ref-type="fig"}). The truncated protein PABPC4L(p.R271X)-mCherry also formed cytoplasmic foci in some cells, but showed significantly less co-localization with G3BP-GFP, suggesting that the p.R271X variant alters the function of the protein (Fig. [2D](#Fig2){ref-type="fig"}).

Discussion {#Sec14}
==========

We identified a rare variant (c.C811T; p.R271X) in PABPC4L segregating in a family with atypical parkinsonian disease (Fig. [1](#Fig1){ref-type="fig"}). Parkinsonism in the family shows peculiar features e.g. rapidly progressing heterogeneous Levodopa unresponsive motor disturbances, early autonomic dysfunction, and additional presence of ataxia, cerebellar atrophy and depression in some affected family members (Figure B and Table [1](#Tab1){ref-type="table"}). Our data together with a previous report of an association of a genomic deletion affecting PABPC4L with treatment resistant depression^[@CR35]^ indicate that genetic abnormalities at PABPC4L locus may cause detrimental changes in brain function. Collectively the data presented in this report extend the genetic and molecular landscape of APDs.

Mouse *pabpc4l* transcript is expressed in several brain areas including cerebellum, hippocampus, cortex and brainstem. The transcript is comparably low prenatally and shows postnatal upregulation with a particularly high expression in the cerebellum of adult mice. Given the regional gene expression in mouse and human brains is generally conserved^[@CR36]^, the postnatal upregulation of cerebellar expression may explain the onset of symptoms in early to middle adulthood (onset between 34 to 47 years) and presentation of disease with cerebellar symptoms and cerebellar atrophy in PABPC4L (c.C811T; p.R271X) variant carriers. Furthermore in the human brain PABPC4L transcript was detected in several brain regions with motor and autonomic functions (Supplementary Fig. [2](#MOESM1){ref-type="media"}, image credit: Human microarray data from the Allen Brain Atlas^[@CR30]^. Taken together the expression pattern of PABPC4L in brain support the involvement PABPC4L (c.C811T; p.R271X) variant in the clinical outcome observed in the family.

Molecular functions and cellular roles of PABPC4L are currently not known. We here show that wild-type PABPC4L redistributes from a predominantly nuclear to focal cytoplasmic pattern and co-localizes with G3BP upon stress induction (Fig. [2C,D](#Fig2){ref-type="fig"}). This suggests that PABPC4L may associate with stress granules similar to cytoplasmic PABP family members PABPC1 and PABPC4^[@CR33],[@CR34]^. Unlike PABPC1 and PABPC4, PABPC4L has not been shown to bind poly(A) RNA as yet and PABPC4L lacks an extended carboxy-terminus shared by PABPC1 and PABPC4^[@CR37],[@CR38]^. However, since the additional carboxy-terminal sequence is dispensible for viability in yeast or PABP function in Xenopus, PABPC4L may thus share stress granule associated function with PABPC1 and PABPC4^[@CR39],[@CR40]^. Our observations also corroborate data from an interactome study, which reported PABPC4L as an interacting partner of the two core stress granule proteins CSDE1and PQBP1, both of which are indispensable for functional G3BP containing stress granules^[@CR41]--[@CR43]^. More importantly, the truncated PABPC4L protein due to the p.R271X variant shows altered subcellular localization in unstressed cells and diminished stress granule association upon stress induction which may result in functional haploinsufficiency of PABPC4L in the c.C811T; p.R271X carriers and thus may be the cause of disease in the patients.

Our study adds to the growing information supporting a role of stress granule associated proteins and RNA metabolism in neurodegenerative pathologies. Stress granules protect cellular RNAs from oxidative damage and promote selective translation of stress response proteins^[@CR10],[@CR44],[@CR45]^. Formation of stress granules also protects cells from stress-induced apoptosis by promoting the activity of the antioxidant enzyme USP10^[@CR46],[@CR47]^. Moreover, defective stress granules may promote protein aggregation and contribute to formation of intracellular inclusions^[@CR48]^.The findings of this study should however be treated with caution due to the use of heterologous expression model such as HEK293. We selected HEK293 cells primarily because they express major stress granule proteins endogenously including PABP family members (<https://www.proteinatlas.org>) and stress granules can robustly be induced in HEK293 cells. Thus HEK293 cells are frequently used for investigating stress granule associated proteins^[@CR49]--[@CR51]^. Predominant exclusion of the truncated PABPC4L protein from stress granules upon induction of stress in HEK293 cells as observed in our study warrants further investigation in more sophisticated, tractable and accurate cellular disease models such as patient-derived iPSCs or neuronal cells to understand a link between neurodegeneration and altered cellular distribution of PABPC4L in p.R271X variant carriers.

Conclusions {#Sec15}
===========

In conclusion, a truncating variant in RNA stress granule associated protein PABPC4L was identified as the potential cause for familial atypical parkinsonism. Our data indicate cytosolic mislocalization of truncated PABPC4L in unstressed and stressed cells. Future studies focusing on the role of stress granule recruitment of PABPC4L and its relevance to the cellular stress responses may unravel novel mechanism of neurodegeneration.
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